StockNews.com upgraded shares of Tactile Systems Technology (NASDAQ:TCMD – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday.
Other research analysts have also issued reports about the company. B. Riley initiated coverage on Tactile Systems Technology in a report on Thursday, September 26th. They set a “buy” rating and a $23.00 target price on the stock. Oppenheimer cut shares of Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. Finally, BTIG Research downgraded shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating in a report on Tuesday, November 5th.
View Our Latest Stock Report on TCMD
Tactile Systems Technology Trading Up 0.3 %
Hedge Funds Weigh In On Tactile Systems Technology
A number of hedge funds have recently added to or reduced their stakes in TCMD. Arcadia Investment Management Corp MI acquired a new position in Tactile Systems Technology in the third quarter valued at about $29,000. Gladius Capital Management LP bought a new position in Tactile Systems Technology in the 3rd quarter valued at about $44,000. Quarry LP acquired a new position in shares of Tactile Systems Technology in the 2nd quarter valued at approximately $46,000. SG Americas Securities LLC bought a new stake in shares of Tactile Systems Technology during the 3rd quarter worth approximately $156,000. Finally, Magnetar Financial LLC acquired a new stake in shares of Tactile Systems Technology during the 2nd quarter worth approximately $130,000. Institutional investors own 83.43% of the company’s stock.
About Tactile Systems Technology
Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.
Featured Stories
- Five stocks we like better than Tactile Systems Technology
- The Risks of Owning Bonds
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.